Given the high incidence of RVO-related macular edema, the difficulty in predicting the therapeutic effect, the burden of anti-VEGF therapy, and the frequency of follow-ups, it is essential to develop a novel approach for individualized prediction of the therapeutic effect (Wecker et al., 2017). This evidence concerns the gene VEGFA and macular retinal edema.